Gantacurium chloride

Drug Profile

Gantacurium chloride

Alternative Names: AV 430A; Gantacurium; GW-280430

Latest Information Update: 02 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Avera Pharmaceuticals
  • Class Anaesthetics; Isoquinolines
  • Mechanism of Action Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Anaesthesia

Most Recent Events

  • 02 Feb 2011 No development reported - Phase-II for Anaesthesia in USA (IV-injection)
  • 29 Jun 2006 Avera Pharmaceuticals has completed a phase II trial with gantacurium as an adjunct to general anaesthesia in the US
  • 30 Nov 2005 Gantacurium is available for licensing worldwide (http://www.averapharm.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top